SecBot

SecBot
NYSE· Pharmaceutical Preparations· Inc. NJ· CIK 0000200406

JNJ

JOHNSON & JOHNSON
$258.14 ▼ -0.20%
Prev close $258.66
Market cap$644.8B
ConsensusBuy
12-mo target$279.27 (+8.8%)
▲ Bullish
Analyst conviction 7/10
Insider Selling Cluster (2 insiders)High Impact Filing (7/10)39 New Institutional Positions11 Institutional ExitsCongressional Activity (4) Biotech & Drug Discovery
Snapshot
The big-picture read on JNJ right now — valuation, ownership and activity at a glance.
Market Cap
$644.8B
Cap Size
Mega Cap
Analyst Consensus
Strong Buy (71%)
Inst. Holders
50 funds
Inst. Value
$330.5B
Inst. Activity
39 buys / 11 sells
Insider Activity
$0.00 buy / $71.5M sell
Insider Net $
-$71.5M
Social Sentiment
75° Bullish
SEC Reports
16
Congressional
17 trades
Price chart 30d -6.2%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 2, 2026 clinical_trial_readout
T-90d Trial Readout: Ibrutinib (Phase 3)
Trial: A Long-term Extension Study of PCI-32765 (Ibrutinib) Sponsor: Janssen Research & Development,
Sep 24, 2026 Event
Owens et al v. Johnson & Johnson et al
Court ruling (cand) — Docket: 3:25-cv-11129
Sep 11, 2026 SEC
A district court dismissed a product liability complaint against Johnson & Johnson without prejudice, granting leave to
COURT-RULING — Impact 1/10
Sep 10, 2026 Event
Xarelto
WARNING: (A) PREMATURE DISCONTINUATION OF XARELTO INCREASES THE RISK OF THROMBOTIC EVENTS, (B) SPINA
Sep 8, 2026 Insider
HEWSON MARILLYN A was granted 180.956 shares
Director @ $276.31 ($50.0K)
Sep 8, 2026 Insider
Woods Eugene A. was granted 135.717 shares
Director @ $276.31 ($37.5K)
Sep 8, 2026 Insider
Pinto Daniel E was granted 113.098 shares
Director @ $276.31 ($31.3K)
Aug 27, 2026 Congress
Thomas Kean Jr sell
$1,001 - $15,000 — House
Analyst ratings buy % +22.4%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Buy 71% rate it Buy or better · 31 analysts
Strong Buy 7 23% Buy 15 48% Hold 9 29% Sell 0 0% Strong Sell 0 0%
Recent analyst actions
DateFirmActionRatingFirm rating
Sep 29, 2026JP MorganMAINTAINNeutral 55%
Sep 10, 2026HSBCMAINTAINBuy 55%
Sep 2, 2026UBSMAINTAINBuy 55%
Aug 6, 2026GuggenheimMAINTAINBuy 52%
Aug 3, 2026Wells FargoMAINTAINOverweight 54%
Jul 17, 2026GuggenheimREITERATEBuy 52%
Jul 16, 2026Raymond JamesMAINTAINOutperform 54%
Jul 16, 2026RBC CapitalREITERATEOutperform 55%
Jul 16, 2026Wells FargoMAINTAINOverweight 54%
Jul 16, 2026Morgan StanleyMAINTAINOverweight 55%
Monthly consensus history
PeriodStr. BuyBuyHoldSellStr. SellBuy %Distribution
Sep 1, 202671590071%
Aug 1, 202671590071%
Jul 1, 2026714100068%
Jun 1, 2026714100068%
May 1, 2026614120063%
Apr 1, 2026614120063%
Mar 1, 2026613130059%
Feb 1, 2026613130059%
Price targets
Where 22 covering analysts think JNJ trades over the next 12 months.
$279.27 +8.8% upside Buy
Current$256.64 Low$190.00 Median$283.50 High$320.00 22 analysts
$190.00$320.00
Analyst rating Buy· 1.9/5 as of Oct 2, 2026
Social media sentiment mood +0.0%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
75°
Bullish
BearishNeutralBullish
18 mentions 12 bullish 1 bearish 5 neutral
Recent posts
stocks Neutral 8d 8h ago
How is my starter setup
▲ 1 · 💬 7· ⚡ 0.5
investing Neutral 1mo ago
Planning to retire in 2 years. Am 48.
▲ 1 · 💬 7· ⚡ 0.5
stocks Bullish 1mo ago
Any suggestions on dividend paying stocks?
▲ 1 · 💬 5· ⚡ 0.5
wallstreetbets Bearish 1mo ago
Hayden Panettiere Johnson & Johnson market short?
▲ 1 · 💬 13· ⚡ 0.5
wallstreetbets Neutral 1mo ago
$JNJ supporting WSB since the 80’s
▲ 1 · 💬 0· ⚡ 0.5
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
16 SEC filing reports analyzed · 3 bullish, 2 bearish, 1 mixed, 10 neutral · avg impact 3.5/10.
BULLISHANALYST-UPGRADE3/10
Leerink Partners double upgrades to Outperform — PT $265 (+18%)
May 13, 2026
NEUTRALCOURT-RULING1/10
A district court dismissed a product liability complaint against Johnson & Johnson without prejudice
Sep 11, 2026
NEUTRALCLUSTER2/10
CEO Joaquin Duato and EVP Jennifer Taubert sold a combined $30.65M in open-market stock over a 5-day
Aug 18, 2026
NEUTRALCLUSTER2/10
JNJ CEO Joaquin Duato and EVP/Chief Legal Officer Elizabeth Forminard sold a combined $29.11M in ope
Aug 15, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Oct 2, 2026
Clinical Trial
A Long-term Extension Study of PCI-32765 (Ibrutinib)
Phase Phase 3 — ACTIVE_NOT_RECRUITING
Oct 2, 2026
clinical_trial_readout
T-90d Trial Readout: Ibrutinib (Phase 3)
Trial: A Long-term Extension Study of PCI-32765 (Ibrutinib) Sponsor: Janssen Research & Development, LLC Phase: Phase 3 | Status: ACTIVE_NOT_RECRUITIN
Oct 1, 2026
Clinical Trial
A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder
Phase Phase 3 — ACTIVE_NOT_RECRUITING
Oct 1, 2026
clinical_trial_readout
T-90d Trial Readout: Cetrelimab (Phase 3)
Trial: A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC
Sep 30, 2026
short_volume
Short Volume: JNJ — 55.1% short (0.9M / 1.7M)
Short: 946,856 | Exempt: 8,054 | TRF Vol: 1,718,653 | Short Ratio: 55.1% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
PeriodEPS Est.RangeGrowth30d RevUp/DnRevenue#
Current Q$2.48$2.31–$2.66-11.4%+2.3%—$25.3B8
Next Q$2.96$2.74–$3.1320.2%-2.3%—$26.6B7
Current FY$11.08$11.01–$11.222.7%+0.3%—$101.3B8
Next FY$12.00$11.30–$13.478.3%-2.5%—$108.6B7
Current-quarter EPS estimate — revision history
WhenEPS estimateChange vs now
Current$2.482—
7d ago$2.453+0.028
30d ago$2.425+0.057
60d ago$2.310+0.172
90d ago$3.024-0.542
Institutional ownership
Which big funds own JNJ (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $330.5B total value (1,300,644,389 shares) as of 2026-Q2. Top holders: BlackRock,, VANGUARD, STATE. Net buying activity: 39 institutions added/increased vs 11 reduced.
Top holders — 2026-Q2
FundSharesValue% TrackedLast move
BlackRock, Inc.212,098,264$53.9B16.3%—
VANGUARD CAPITAL MANAGEMENT LLC157,226,374$39.9B12.1%—
STATE STREET CORP133,776,025$34.0B10.3%—
VANGUARD PORTFOLIO MANAGEMENT LLC64,370,816$16.3B4.9%—
JPMORGAN CHASE & CO58,301,609$15.1B4.6%—
GEODE CAPITAL MANAGEMENT, LLC59,086,417$15.0B4.5%—
MORGAN STANLEY44,808,254$11.4B3.4%—
NORGES BANK31,825,084$8.1B2.4%NEW
STATE FARM MUTUAL AUTOMOBILE INSURANCE CO31,590,952$8.0B2.4%—
NORTHERN TRUST CORP28,792,064$7.3B2.2%—
Recent position changes
FundActionPrevCurrentChangeValue
NORGES BANKNEW—31,825,084—$8.1B
Capital World InvestorsADD11,749,36115,215,015+29.5%$3.9B
Fisher Asset Management, LLCADD9,263,61113,307,056+43.6%$3.4B
BARCLAYS PLCTRIM6,786,1074,651,595-31.5%$1.2B
CITIGROUP INCADD2,832,4973,925,186+38.6%$996.9M
MARSHALL WACE, LLPADD2,377,8222,989,537+25.7%$759.3M
Corient Private Wealth LPDOUBLED2,666,9416,060,922+127.3%$672.9M
Bahl & Gaynor LLCTRIM2,721,1831,970,876-27.6%$500.5M
Assenagon Asset Management S.A.ADD1,037,0721,939,364+87.0%$492.5M
Pictet Asset Management Holding SAADD1,460,5291,853,258+26.9%$470.7M
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
22 insiders, 50 transactions. Net -$71.5M — $0.00 bought, $71.5M sold.
DateInsiderTitleTypeSharesPriceValue
Sep 8, 2026HEWSON MARILLYN ADirectorAWARD180.956$276.31$50.0K
Sep 8, 2026Woods Eugene A.DirectorAWARD135.717$276.31$37.5K
Sep 8, 2026Pinto Daniel EDirectorAWARD113.098$276.31$31.3K
Sep 2, 2026Schmid TimothyEVP, WW Chair, MedTechEXERCISE11,070$131.94$1.5M
Sep 2, 2026Schmid TimothyEVP, WW Chair, MedTechSELL11,070$274.74$3.0M
Sep 2, 2026Schmid TimothyEVP, WW Chair, MedTechEXERCISE22,527$151.41$3.4M
Sep 2, 2026Schmid TimothyEVP, WW Chair, MedTechSELL22,527$274.74$6.2M
Aug 17, 2026Taubert Jennifer LEVP, WWC. Innovative MedicineEXERCISE15,000$115.67$1.7M
Aug 17, 2026Taubert Jennifer LEVP, WWC. Innovative MedicineSELL15,000$263.36$4.0M
Aug 13, 2026Duato JoaquinCEO and Chairman of the BoardSELL102,315$261.00$26.7M
Congressional trades
JNJ trades disclosed by members of Congress, with disclosure delay.
5 members · 5 buys / 12 sells
DateMemberPartyChamberTypeAmountAssetDisclosed
Aug 27, 2026Thomas Kean JrRHOUSESELL$1,001 - $15,000Johnson & JohnsonSep 14, 2026(19d)
Aug 20, 2026John BoozmanRSENATESELL$1,001 - $15,000Johnson & JohnsonSep 11, 2026(23d)
Aug 7, 2026Ro KhannaDHOUSESELL$1,001 - $15,000Johnson & JohnsonSep 7, 2026(32d)
Jul 30, 2026Rich McCormickRHOUSESELL$1,001 - $15,000Johnson & JohnsonAug 17, 2026(19d)
Jul 2, 2026Ro KhannaDHOUSEBUY$1,001 - $15,000Johnson & JohnsonAug 12, 2026(42d)
Jun 29, 2026Thomas Kean JrRHOUSESELL$1,001 - $15,000Johnson & JohnsonJul 16, 2026(18d)
Jun 9, 2026Lloyd DoggettDHOUSEBUY$1,001 - $15,000Johnson & JohnsonJul 7, 2026(29d)
Jun 2, 2026Thomas Kean JrRHOUSESELL$1,001 - $15,000Johnson & JohnsonJul 16, 2026(45d)
Apr 13, 2026Ro KhannaDHOUSEBUY$15,001 - $50,000Johnson & JohnsonMay 13, 2026(31d)
Mar 26, 2026Thomas Kean JrRHOUSESELL$1,001 - $15,000Johnson & JohnsonApr 14, 2026(20d)
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for JNJ.
Shares short
21,188,522
Settlement Sep 15, 2026
Change vs prior
-2.2%
Semi-monthly cycle
Days to cover
3.6
At avg daily volume
Of shares outstanding
≈0.9%
Estimate — not % of float
All JNJ filing & press-release reports (16)